Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance.[L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Sulfamethoxazole and Trimethoprim (Double Strength)
Bactrim DS
Septra DS Tablets
Bactrim Roche Inj
Roubac Tab 160/800
Septra Grape
Septra Injection
Trisulfa Tab
Teva-trimel DS
Sulfamethoxazole and Trimethoprim Injection, BP
Septra Pediatric Suspension
Teva-trimel
Sulfatrim Pediatric
Sulfamethoxazole and Trimethoprim for Injection, USP
Sulfamethoxazole Tab 500mg
Nu-cotrimox Sus 40/8mg/ml
Bactrim Roche Tab
Sulfamethoxazole and Trimethoprim Double Strength
Bactrim
Sulfamethox-TMP DS
Sulfatrim DS
Roubac Tab 80/400
Nu-cotrimox-DS Tab 800/160mg
Septra DS
Bactrim DS Roche Tab
Protrin Tab
Sulfamethoxazole and Trimethoprim
SULFAMETHOXAZOLE and TRIMETHOPRIM
SulfatrimTM Pediatric Suspension
Sulfamethoxazole and Trimethoprim Tablets
Trisulfa S Suspension
SULFAMETHOXAZOLE AND TRIMETHOPRIM double strength
Sulfameth/Trimeth-DS
Sulfamethoxazole
Trisulfa DS Tab
Apo Sulfamethoxazole Tab 500mg
Apo-sulfatrim Oral Suspension
Indication
Sulfamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible _Shigella_, prophylaxis and treatment of _Pneumocystis jiroveci_ pneumonia, and travelers' diarrhea caused by enterotoxigenic _E. coli_.[L11830,L11863] In Canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with [gentamicin] or [rifampicin].[L11851]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682